Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06224556

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People

* Non-Communicable Diseases (NCDs) can accelerated the aging process and increase the frailty condition * The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context * Recently, in Italy the first Guidelines about the CGA in different settings for older people has been pubblicated * The CGA can identify older people at high risk of frailty who can benefit from a personalized prevention program * No studies has been investigated the effects of a personalized prevention program (PPP) based on the CGA in a primary care setting * The main hypothesis is that the CGA assessment can result in personalized prevention programs for older subjects in primary care settings with an effect in reducing the hospitalization rate and can be related to the biological paramters in NCDs

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Polimedica Societa' Cooperativa, Bari, Italy

Loading trial locations.

About this study

The main aim of the project is to evaluate in older people the effectiveness of personalized preventive interventions based on the Comprehensive Geriatric Assessment (CGA) in the primary care setting and to explore biological process in Non-Communicable Disases (NCDs).

The study involves 1216 subjects enrolled by General Practitioners (GPs) in four different Italian Areas.

The GPs involved will be randomised to clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group.

The sample size:

A recent Cochrane systematic review reports a significant reduction in the risk of unplanned hospitalisation in community-dwelling elderly persons treated with VMD compared to standard clinical practice (RR= 0.83; CI 95%: 0.70-0.99). Thus, assuming an incidence of unplanned hospitalisations in one year of 38.8% in the group receiving PPP compared to 47.7% in the group randomised to standard care and assuming a power of 80% and a type I error of 5%, a total of 972 participants will be enrolled. Furthermore, assuming a drop-out rate of 20% over the 1-year follow-up period, the final sample will be 1216 participants, 608 in each group

608 subjects will be involved in the intervention group: they will receive the Personalized Prevention Program (PPP) and a saliva sample will be collected.

608 subjects will be involved in the control group according to the normal clinical practice.

Both groups will be contacted at 6 and 12 months after the baseline for the follow-up.

Statistical analyses:

Baseline characteristics will be compared between the group receiving the CGA-based PPP intervention and the control group. Continuous variables will be compared using the t-Student test and categorical variables using the Chi-square test. The cumulative probability of the primary and secondary outcome will be estimated by Kaplan-Meier curve, using the log-rank test to assess differences between the two groups. To assess the risk associated with the primary outcome (rate of unplanned hospitalisation at 12 months) in subjects in the intervention group compared to subjects in standard care, the Hazard Ratio (HR) will be estimated by fitting a Cox model, after testing for proportional hazards. Similarly, the risk of secondary outcomes will be estimated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 65 years old and over
  • At least 1 non-communicable chronic disease
  • Signed informed consent

Exclusion criteria

  • not willing in partecipating in the study and no signed informed consent
  • <65 years old
  • without non-communicable chronic diseases

Treatment and study plan

Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program

Combination Product

Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.

The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).

Saliva sample will be collected and analyzed.

Primary outcomes

  1. Hospitalization rate

    Time frame: 12 months

    Unplanned hospitalization rate

Secondary outcomes

  1. Composed outcome

    Time frame: 6 and 12 months

    Composed outcome including: emergency access rate, hospitalization and institutionalization rates at 6 and 12 months after the baseline.

  2. Number of unplanned General Practitioners visits

    Time frame: 12 months

    Unplanned GPs visits

  3. Mortality rate

    Time frame: 6 and 12 months

    mortality rate at 6 and 12 months

Other outcomes

  1. Adherence at the PPP

    Time frame: 6 and 12 months

    Adherence at the Personalized Prevention Program by the Intervention Group

  2. Psychological Well-being

    Time frame: Baseline, 6 and 12 months

    Psychological well-being assessed to the Intervention Group

  3. Resilience

    Time frame: Baseline, 6 and 12 months

    Resilience outcome evaluated in the Intervention Group

  4. Lactate in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for the Lactate parameter

  5. NAD/NADH in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for theNAD/NADH parameter

  6. TBARS in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for the TBARS parameter

  7. TNF-alfa in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for theTNF-alfa parameter

  8. IL-1b in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for the IL-1b parameter

  9. IL-6 in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for the IL-6 parameter

  10. IL-8 in the Intervention Group

    Time frame: After the saliva collection at the baseline

    Saliva analyses for the IL-8 parameter

  11. Microbioma saliva analysis in a sub-group of the Intervention Group

    Time frame: After the saliva collection at the baseline

    The microbioma saliva sample will be analysed in 210 subjects from the Intervention Group through the DNA GENOTEK OME-505 Omnigene Oral Collection Kits for Nucleic Acid Saliva

Study contacts

Contact information is provided by the study sponsor or research team.

Alberto Pilotto

CONTACT

[email protected]

0039 0105634467

Marina Barbagelata

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Alberto Pilotto

Other

Registry information

Official study title

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People: a Practical Approach in Primary Care Setting

Acronym: PrimaCare_P3

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 25, 2024
Registry last updated
Aug 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.